Help! Please Register
Brokers Arena brokers-arena.com/ Top rated brokers compared
  Education &
  Tools

  Introduction
  Abbreviations
  Links
  CME
  Conference
  Highlights
  Bibliography
  Glossary
  Good Books
  Events
  Calendar


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank


  Mycoses

  Introduction
  Human
  Veterinary
  Environmental
  Industrial
  Agricultural


  Drugs

  Introduction
  Medical
  Veterinary
  Environmental
  Industrial
  Agricultural


  Laboratory

  Introduction
  Susceptibility
  MIC Database
  Procedures
  Histopathology


  About Us

  Introduction
  Our Mission
  Editorial Board
  Editorial Staff
  Supporters
  Contributors
  Legal Stuff
  Privacy Policy



This page updated:


DoctorFungus - All Rights Reserved © 2007 Copyright
& Privacy Policy


Site built and designed for doctorfungus by Webillustrated



You are here: Education & Tools >
Astellas Pharma Inc.

conference highlightsConference Highlights

Focus on Fungal Infections 14


Antifungal Agents
  1. SAFETY AND EFFICACY OF AMBISOME IN PATIENTS WITH FUNGAL INFECTIONS. A POST MARKETING MULTICENTRE SURVEILLANCE STUDY IN TURKEY.
    Anak S and the PMS Study Group
    Istanbul University- School of Medicine, Dept. of Pediatric Hematology/Oncology/BMT, çapa Istanbul, Turkey


  2. ASSESSMENT OF THE PHARMACOKINETICS (PK) OF ANIDULAFUNGIN (ANID) IN PATIENTS WITH INVASIVE ASPERGILLOSIS (IA) RECEIVING CONCOMITANT LIPOSOMAL AMPHOTERICIN B (LAMB).
    Dowell J, Schranz J, Stogniew M, Krause D, Henkel T King of Prussia, USA


  3. SAFETY AND EFFECTIVENESS OF HIGH DOSE/LONG DURATION ABLC THERAPY
    Hooshmand-Rad R1, Reed MD2, Chu A1, Gotz V1, Morris JA1, Batty S3, Dominguez EA4
    1ProSanos Corporation, La Jolla, USA;
    2School of Medicine, Department of Pediatrics, Case Western Reserve University, Cleveland, USA;
    3ENZON Pharmaceuticals, Bridgewater, USA; 4Department of Medicine, Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, USA


  4. USE OF AMPHOTERICIN B LIPID COMPLEX (ABLC) IN PATIENTS OVER 65 YEARS
    Hooshmand-Rad R1, Chu A1, Gotz V1, Morris JA1, Batty S2, Freifeld A 3
    1ProSanos Corporation, La Jolla, USA;
    2ENZON Pharmaceuticals, Bridgewater, USA;
    3Department of Medicine, University of Nebraska Medical Center, Omaha, USA


  5. ORAL DELIVERY OF AMPHTERICIN B COCHLEATES: DEVELOPMENTAL STATUS
    Mannino RJ1, Ahl PL1, Delmarre D1, Fogerite SG1, Ngoje J1, Tan F1, Lu R1, Sandulow J1, Kalbag S1, Machado H2, Mumper R2, Delmas G3 and Perlin D3
    1BioDelivery Sciences International, Inc., Newark, USA
    2Center for Pharmaceutical Science and Technology, University of Kentucky, Lexington, USA
    3Public Health Research Institute at the International Center for Public Health, Newark, USA


  6. ANTIFUNGAL PROPHYLAXIS IN 771 PATIENTS (PTS) WITH HEMATOLOGICAL MALIGNANCIES: IS THERE A PERFECT DRUG ?
    Mattiuzzi G, Alvarado G, Zhou X, Giles FJ, Bekele BN, Estey E and Kantarjian H
    The University of Texas M.D. Anderson Cancer Center. Houston, USA


  7. EVALUATING EFFICACY OF SYSTEMIC ANTIFUNGALS FOR ESOPHAGEAL CANDIDIASIS: A COMPARISON OF CLINICAL TRIAL DESIGNS
    Navarro E, Dixon C, Powers JH
    Office of Drug Evaluation IV, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, USA


  8. CASPOFUNGIN HEPATOTOXICITY AND CLINICAL EXPERIENCE IN AN ORGAN TRANSPLANT POPULATION
    Simoneau E1, Poirier C2, Mendola A3 and Lemieux C1
    1Dept of Microbiology-Infectious Diseases, 2Dept of Medecine and 3Dept of Pharmacy, Hôpital Notre-Dame du CHUM and Université de Montreal, Montreal, Canada


  9. TWICE WEEKLY FLUCONAZOLE PROPHYLAXIS FOR PREVENTION OF INVASIVE FUNGAL INFECTION IN HIGH-RISK PRETERM INFANTS LESS THAN 1000 GRAMS.
    Kaufman D1, Boyle R 1, Hazen KC2, Patrie JT 3, Robinson M1 and Grossman LB1.
    1Pediatrics;
    2Pathology and Microbiology and 3Biostatistics, University of Virginia, Charlottesville, USA


  10. ELIMINATION OF ASPERGILLUS AS A SIGNIFICANT PATHOGEN IN AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PROGRAM AFTER INTRODUCTION OF ROUTINE LONG-TERM ITRACONAZOLE PROPHYLAXIS.
    Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo M
    Stem cell Transplant Program/Department of Medicine, UCLA Medical Center, Los Angeles, USA


top of page    




View other categories
Antifungal Agents | Antifungal Combinations | Antifungal Susceptibility | Basic Mycology
Case Reports | Clinical Mycology | Animal Models | Diagnostics | View All





  Home | Image Bank | Lecture Bank | Knowledgebase | Site Map | Contact Us |
The Fungi | Mycoses | Drugs |
Laboratory | Education & Tools | About Us

  mycosesstudygroup.org's sponsors